Odysight.Ai Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Odysight.Ai Inc. on October 22, 2024. The filing addresses Item 5.02 regarding the appointment and compensatory arrangements for Dr. Carlo Papa, who was appointed to the Board of Directors on September 16, 2024.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and does not contain financial performance data for the period.
Material Changes
The primary material change reported is the approval of a new compensation package for Dr. Carlo Papa, replacing the standard quarterly director fees previously outlined in the Company's 2024 Form 10-K. The new package includes:
- Cash Compensation: €30,000 annual fee for Board service and €120,000 annual fee for serving as chairman of a planned European subsidiary (subject to entity incorporation and budget approval).
- Equity Award: Options to purchase 30,000 shares of common stock under the 2024 Stock Incentive Plan with an exercise price of $4.80 per share.
- Vesting Schedule: One-third vests on the first anniversary of the grant date; the remainder vests over two years in eight equal quarterly installments. Vesting accelerates upon a change of control.
- Performance Bonus: An incentive/performance-based bonus with parameters to be determined by the Board at a future date.
Guidance, Outlook, and Risks
The Company intends to form a European subsidiary in the near future to pursue business opportunities in Europe. The €120,000 compensation component for Dr. Papa is contingent upon the incorporation of this entity and the Board's final approval of its business plan and budget. No specific financial guidance or risk factors beyond the standard contingencies of the new subsidiary formation are detailed in this filing.
Investor Verification Checklist
- Verify the incorporation status of the planned European subsidiary to confirm the €120,000 compensation obligation.
- Review the Company's 2024 Stock Incentive Plan to understand the full terms of the 30,000 share option grant.
- Monitor future Board announcements for the determination of performance bonus parameters for Dr. Papa.
- Confirm the total dilution impact of the 30,000 new options on existing shareholders.